Prof Cmelak talks to ecancertv at ASCO 2014 about the findings of an NIH-funded phase II study which suggest that certain patients with human papilloma virus (HPV)-positive oropharyngeal cancer can safely receive lower- dose radiation therapy, using a new approach that customises radiation dose based on response to induction chemotherapy and other prognostic factors.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.